ritanserin has been researched along with Kidney Failure, Chronic in 1 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The regular hemodialysis sessions every 2-3 days did not affect the elimination rate of ritanserin, as the terminal half-life in these patients (39 +/- 23 hr) is similar to that in healthy volunteers (41 +/- 14 hr)." | 2.67 | Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ( Heykants, J; Huang, ML; Koch, S; Kokot, F; Kuska, J; Van Peer, A; Zazgornik, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zazgornik, J | 1 |
| Kuska, J | 1 |
| Kokot, F | 1 |
| Koch, S | 1 |
| Van Peer, A | 1 |
| Huang, ML | 1 |
| Heykants, J | 1 |
1 trial available for ritanserin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
Topics: Administration, Oral; Adult; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1991 |